Direct chemiluminescence immunoassay (CLIA) for muramyl tripeptide phosphatidyl-ethanolamine in plasma.

J Biolumin Chemilumin

Pharma Research and Development, CIBA-GEIGY AG, Basle, Switzerland.

Published: September 1991

AI Article Synopsis

  • A competitive chemiluminescent immunoassay has been developed to measure muramyl tripeptide phosphatidyl-ethanolamine (MTP-PE) in plasma using an acridinium ester-labelled analogue and rabbit antiserum.
  • The assay achieves a high sensitivity (0.012 nmol/l) and a broad working range (0.1-30,000 nmol/l) with minimal variability (inter-assay CVs ≤ 10%).
  • Rat plasma studies showed that MTP-PE concentrations decline quickly after intravenous infusion, with specific half-lives and clearance rates determined for the compound in the body.

Article Abstract

A competitive chemiluminescent immunoassay for quantitation of muramyl tripeptide phosphatidyl-ethanolamine (MTP-PE) in plasma has been developed. The assay is based on the use of an acridinium ester-labelled analogue of muramyl tripeptide and a rabbit antiserum. It includes an overnight incubation and a separation with a second antibody covalently coupled to paramagnetic particles. The sensitivity of detection is 0.012 nmol/l, the assay working range is 0.1-5 nmol/l, and the inter-assay CVs are less than or equal to 10%. Using up to 6000-fold sample dilutions, a wide working range (0.1-30,000 nmol/l) is obtained. Rat plasma samples were collected during and one day after intravenous infusion of MTP-PE. Following infusion, the concentrations in plasma declined multiphasically. Half-life time was 0.37 h +/- 0.03 (mean +/- SD, alpha phase) and 1.76 h +/- 0.08 (mean +/- SD, beta phase), clearance and volume of distribution were 0.09 +/- 0.02 l/h x kg (mean +/- SD) and 0.06 +/- 0.01 l/kg (mean +/- SD) respectively. The use of an acridinium ester as a chemiluminescent (CL) label overcomes the problems associated with reagents of limited shelf-life.

Download full-text PDF

Source
http://dx.doi.org/10.1002/bio.1170060204DOI Listing

Publication Analysis

Top Keywords

muramyl tripeptide
12
tripeptide phosphatidyl-ethanolamine
8
working range
8
+/-
8
direct chemiluminescence
4
chemiluminescence immunoassay
4
immunoassay clia
4
clia muramyl
4
plasma
4
phosphatidyl-ethanolamine plasma
4

Similar Publications

Inducing phospholipase A2 and cyclooxygenase-2 expression and prostaglandins' production of human dental pulp cells by activation of NOD receptor and its downstream signaling.

Int J Biol Macromol

December 2024

School of Dentistry, National Taiwan University Medical College, Taipei, Taiwan; Department of Dentistry, National Taiwan University Hospital, Taipei, Taiwan; School of Dentistry, College of Dental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Dentistry, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. Electronic address:

Dental caries with invasion and infection by microorganisms may induce pulpitis and intolerable pain. L-Ala-γ-D-Glu-mDAP (TriDAP) is a DAP-comprising muramyl tripeptide and a peptidoglycan degradation product found in gram-negative pulpal pathogens. TriDAP activates nucleotide-binding oligomerization domain1/2 (NOD1/NOD2) and induces tissue inflammatory responses.

View Article and Find Full Text PDF

PGLYRP-1 mediated intracellular peptidoglycan detection promotes mucosal protection.

Res Sq

October 2024

Department of Medicine, Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, 5959 Harry Hines Boulevard, Dallas, Texas 75390, United States.

Article Synopsis
  • * PGLYRP-1 is essential for innate immune response in macrophages when triggered by a specific PGN disaccharide (GMTriP-K), but not by other similar compounds, indicating a unique signaling pathway.
  • * The study found that PGLYRP-1 interacts with other proteins in cells, localizes to specific cellular structures, and is involved in regulating gene expression linked to intestinal inflammation in both mice and humans.
View Article and Find Full Text PDF

Hematopoietic stem-cell transplantation (HSCT) has emerged as a groundbreaking therapeutic option for acute myeloid leukemia (AML) and specific subtypes of acute lymphoblastic leukemia (ALL). The prognostic significance of the NOD2/CARD15 gene has been explored alongside various factors, encompassing diverse patient cohorts and gene variants. Siblings and unrelated donors used for stem cell transplantation exhibit significant associations between their genetic variations and graft-versus-host disease incidence.

View Article and Find Full Text PDF

Lipopolysaccharide-binding protein expression is associated to the metastatic status of osteosarcoma patients.

J Bone Oncol

October 2022

Institut de Cancérologie de l'Ouest, Tumour Heterogeneity and Precison Medicine Laboratory, Saint-Herblain, France.

Article Synopsis
  • Osteosarcoma (OS) is a rare and aggressive bone cancer with a complex genetic and cellular makeup, and survival rates have remained stagnant for 40 years despite advances in treatment.
  • The study investigated the role of lipopolysaccharide (LPS)-binding protein (LBP) in OS biopsies, finding higher LBP levels in local disease compared to metastatic cases, indicating the possible involvement of Gram-negative bacteria.
  • The findings suggest that the microbiome associated with OS could be crucial for developing new therapies aimed at improving treatment outcomes based on the tumor microenvironment.
View Article and Find Full Text PDF

Cancer immune therapy using engineered ‛tail-flipping' nanoliposomes targeting alternatively activated macrophages.

Nat Commun

August 2022

Engineered Therapeutics, Department of Advanced Organ bioengineering and Therapeutics, TechMed Centre, University of Twente, Drienerlolaan 5, 7500AE, Enschede, The Netherlands.

Alternatively-activated, M2-like tumor-associated macrophages (TAM) strongly contribute to tumor growth, invasiveness and metastasis. Technologies to disable the pro-tumorigenic function of these TAMs are of high interest to immunotherapy research. Here we show that by designing engineered nanoliposomes bio-mimicking peroxidated phospholipids that are recognised and internalised by scavenger receptors, TAMs can be targeted.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!